Adipositas und Diabetes

Jens Aberle; Anne Lautenbach; Svenja Meyhöfer; Sebastian M. Meyhöfer; Markus Menzen; Lars Selig; Knut Mai; Matthias Blüher

doi:10.1055/a-2076-0105

Diabetologie und Stoffwechsel, Inhaltsverzeichnis

Diabetologie und Stoffwechsel 2023; 18(S 02): S305-S313
DOI: 10.1055/a-2076-0105

DDG-Praxisempfehlung

Adipositas und Diabetes

Jens Aberle

¹Endokrinologie und Diabetologie, Universitäres Adipositas Centrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

,

Anne Lautenbach

¹Endokrinologie und Diabetologie, Universitäres Adipositas Centrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

,

Svenja Meyhöfer

²Institut für Endokrinologie & Diabetes, Universität zu Lübeck, Endokrinologie, Diabetologie und Stoffwechsel, Medizinische Klinik 1, UKSH – Campus Lübeck, Lübeck, Deutschland

,

Sebastian M. Meyhöfer

²Institut für Endokrinologie & Diabetes, Universität zu Lübeck, Endokrinologie, Diabetologie und Stoffwechsel, Medizinische Klinik 1, UKSH – Campus Lübeck, Lübeck, Deutschland

,

Markus Menzen

³Abteilung für Innere Medizin, Diabetologie, Gemeinschaftskrankenhaus Bonn, Bonn, Deutschland

,

Lars Selig

⁴Ernährungsteam/Ernährungsambulanz, Universitätsklinikum Leipzig – AoR, Leipzig, Deutschland

,

Knut Mai

⁵Medizinische Klinik für Endokrinologie und Stoffwechselmedizin (einschl. Arbeitsbereich Lipidstoffwechsel), Charité Universitätsmedizin Berlin, Berlin, Deutschland

,

Matthias Blüher

⁶Klinik und Poliklinik für Endokrinologie und Nephrologie, Universitätsmedizin Leipzig, Leipzig, Deutschland

Literatur
1 Lindström J, Louheranta A, Mannelin M. et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26: 3230-3236
2 Knowler WC, Barrett-Connor E, Fowler SE. et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med 2002; 346: 393-403
3 Lean MEJ, Powrie JK, Anderson AS. et al. Obesity, Weight Loss and Prognosis in Type 2 Diabetes. Diabet Med 1990; 7: 228-233
4 Williamson DF, Thompson TJ, Thun M. et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-1504
5 Wing RR, Bahnson JL, Bray GA. et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: Four-year results of the look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575
6 Eeg-Olofsson K, Cederholm J, Nilsson PM. et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: An observational study in 13,087 patients. Diabetologia 2009; 52: 65-73
7 Davies M, Aroda VR, Collins BS. et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45: 2753-2786
8 Wang Z, Hoy WE. Waist circumference, body mass index, hip circumference and waist-to-hip ratio as predictors of cardiovascular disease in Aboriginal people. Eur J Clin Nutr 2004; 58: 888-893
9 Pischon T, Boeing H, Hoffmann K. et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120
10 Evert AB, Dennison M, Gardner CD. et al. Nutrition therapy for adults with diabetes or prediabetes: A consensus report. Diabetes Care 2019; 42: 731-754
11 Churuangsuk C, Hall J, Reynolds A. et al. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia 2022; 65: 14-36
12 Hansen TT, Astrup A, Sjödin AL. et al. Are Dietary Proteins the Key to Successful Body Weight Management? A Systematic Review and Meta-Analysis of Studies Assessing Body Weight Outcomes after Interventions with Increased Dietary Protein. Nutrients 2021; 13: 3193
13 Lean ME, Leslie WS, Barnes AC. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, clusterrandomised trial. Lancet 2018; 391: 541-551
14 Gregg EW, Chen H, Wagenknecht LE. et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012; 308: 2489-2496
15 Nationale VersorgungsLeitlinie (NVL) Typ-2-Diabetes. 1. Aufl.
16 Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: A systematic review of the literature. Obes Rev 2006; 7: 183-200
17 ElSayed NA, Aleppo G, Aroda VR. et al. on behalf of the American Diabetes Association Diabetes Care. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes – 2023. Diabetes Care 2023; 46 (Suppl. 01) S128-S139
18 Vilsbøll T, Christensen M, Junker AE. et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and metaanalyses of randomised controlled trials. BMJ 2012; 344: d7771
19 Pi-Sunyer X, Astrup A, Fujioka K. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373: 11-22
20 Wilding JPH, Batterham RL, Calanna S. et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384: 989-1002
21 Rubino DM, Greenway FL, Khalid U. et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 2022; 327: 138-150
22 Rosenstock J, Wysham C, Frías JP. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021; 398: 143-155
23 Frías JP, Davies MJ, Rosenstock J. et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021; 385: 503-515
24 Jastreboff AM, Aronne LJ, Ahmad NN. et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022; 387: 205-216
25 Garvey WT, Frias JP, Jastreboff AM. et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023; 402: 613-626
26 Rubino F, Nathan DM, Eckel RH. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Diabetes Care 2016; 39: 861-877
27 S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen. Version 2.3 (Februar 2018).
28 Flum DR, Belle SH, King WC. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. et al. Perioperative Safety in the Longitudinal Assessment of Bariatric Surgery. N Engl J Med 2009; 361: 445-454
29 Birkmeyer NJO, Dimick JB, Share D. et al. Hospital complication rates with bariatric surgery in Michigan. JAMA 2010; 304: 435-442
30 Aberle J, Reining F, Dannheim V. et al. Metformin after bariatric surgery – An acid problem. Exp Clin Endocrinol Diabetes 2012; 120: 152-153